Last Updated: 2026-03-31 PT
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder classified as an alpha-synucleinopathy. Despite being part of the same pathological family as [Parkinson's Disease](/diseases/parkinsons-disease) and [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies), MSA has received significantly less research attention and funding. This gap analysis identifies the critical knowledge gaps that, if addressed, could accelerate therapeutic development for this devastating disease.
Last Updated: 2026-03-31 PT
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder classified as an alpha-synucleinopathy. Despite being part of the same pathological family as [Parkinson's Disease](/diseases/parkinsons-disease) and [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies), MSA has received significantly less research attention and funding. This gap analysis identifies the critical knowledge gaps that, if addressed, could accelerate therapeutic development for this devastating disease.
This analysis compares MSA-specific gaps against the broader alpha-synucleinopathy landscape, drawing on the more extensively characterized PD and DLB research priorities documented in [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) and [Dementia with Lewy Bodies Knowledge Gaps](/gaps/dementia-lewy-bodies).
| Dimension | Parkinson's Disease | Dementia with Lewy Bodies | Multiple System Atrophy |
|-----------|-------------------|-------------------------|------------------------|
| Prevalence | ~10 million worldwide | ~1.1 million | ~1.9-4.9 per 100K |
| Research investment | High | Moderate | Very low |
| Disease-modifying trials | Active (GLP-1, LRRK2) | Limited | Essentially none |
| Genetic risk factors | Well-characterized | Emerging | Partially characterized |
| Biomarker infrastructure | PPMI, extensive SAA data | Limited | Minimal |
| Animal models | Multiple validated models | Partial | Poorly developed |
| Knowledge gap documentation | Extensive | Growing | Almost absent |
The relative scarcity of MSA research creates a compound disadvantage:
Knowledge gaps are ranked using a multi-dimensional scoring system adapted from other gap analyses in the wiki:
Gaps are categorized as:
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 1 | What determines the oligodendrocyte-specific vulnerability to α-synuclein aggregation in MSA (vs neuronal vulnerability in PD/DLB)? | 10 | 8 | 10 | 7 | 35 | This is the fundamental biological question distinguishing MSA. Understanding this could reveal novel therapeutic targets. |
| 2 | Can we develop validated diagnostic biomarkers for MSA to distinguish it from PD and PSP? | 10 | 7 | 10 | 6 | 33 | Misdiagnosis rates of 30%+ in early stages confound all research. |
| 3 | What is the natural history of MSA subtypes (MSA-P vs MSA-C) and what determines phenotype? | 9 | 8 | 9 | 7 | 33 | Better phenotyping would enable subtype-specific clinical trials. |
| 4 | Why does MSA progress so much faster than PD (6-10 years vs 15-20 years median survival)? | 10 | 6 | 9 | 6 | 31 | Rapid progression limits therapeutic window. Understanding mechanisms could reveal intervention points. |
| 5 | What are the optimal outcome measures for MSA clinical trials? | 9 | 7 | 9 | 6 | 31 | No validated disease progression biomarkers. Trials use PD measures that may not capture MSA-specific decline. |
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 6 | What is the role of glial cytoplasmic inclusions (GCIs) in oligodendrocyte dysfunction—are they toxic or protective? | 8 | 7 | 9 | 6 | 30 | GCIs are the pathological hallmark but their functional role is unclear. |
| 7 | Can we develop animal models that faithfully recapitulate MSA pathology? | 9 | 6 | 9 | 5 | 29 | Poor model availability is a major barrier to therapeutic development. |
| 8 | What is the relationship between autonomic failure timing and disease progression in MSA? | 8 | 7 | 8 | 6 | 29 | Autonomic dysfunction is a defining feature but its relationship to motor progression is poorly understood. |
| 9 | Do GBA and other genetic variants modify MSA phenotype similarly to PD, or differently? | 8 | 7 | 8 | 6 | 29 | Genetic understanding could inform patient stratification. |
| 10 | What drives the poor levodopa response in MSA-P vs good response in PD? | 8 | 7 | 8 | 6 | 29 | Understanding this could reveal mechanisms of dopaminergic degeneration. |
| 11 | Can neurofilament light chain (NfL) be used for prognostic stratification in MSA? | 8 | 8 | 7 | 7 | 30 | NfL is elevated but predictive utility is unclear. |
| 12 | What is the role of myelin dysfunction in MSA pathogenesis—primary or secondary? | 7 | 7 | 8 | 6 | 28 | Myelin loss is prominent but its contribution to disease is unknown. |
| Rank | Knowledge Gap | Impact | Tractability | Under-exploration | Data | Total | Why It Matters |
|------|---------------|--------|---------------|-------------------|------|-------|----------------|
| 13 | How does α-synuclein strain differ between MSA, PD, and DLB? | 7 | 6 | 8 | 6 | 27 | Strain differences may explain different clinical presentations. |
| 14 | What is the relationship between REM sleep behavior disorder (RBD) and MSA—prodromal marker or parallel process? | 7 | 7 | 7 | 6 | 27 | RBD is common but its diagnostic utility in MSA is unclear. |
| 15 | Can we identify MSA-specific alpha-synuclein seed amplification assay patterns? | 7 | 6 | 8 | 5 | 26 | SAA is validated for PD but not MSA. |
The relationship between MSA and PD represents a critical knowledge gap. Both are α-synucleinopathies, but with fundamentally different cellular targets:
Shared mechanisms:
DLB shares with MSA the feature of autonomic dysfunction, but the timing and severity differ:
Based on the gap analysis, the following research directions would have highest impact:
The following diagram shows the key molecular relationships involving MSA Knowledge Gaps — Alpha-Synucleinopathy Research Priorities discovered through SciDEX knowledge graph analysis: